Product Code: RP-ID-10074177 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10074177
Market Overview:
Global G-CSF Biosimilars Market Size study, by Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies) and Regional Forecasts 2018-2025
Global G-CSF Biosimilars Market to reach USD XX billion by 2025.
Global G-CSF Biosimilars Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The G-CSF Biosimilars Market is continuously growing across the world over the coming years. Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000. GCSF stimulates granulocyte production in BM suppressed by chemotherapy and radiotherapy and reduces infections in cancer patients. It can induce terminal maturation of myeloid leukemia cells, resulting in complete hematologic and cytologic remission, and can suppress self-renewal. It is useful in patients with AIDS or leukemic relapse after allogeneic BM transplantation. Increasing aging population, growing incidence of chronic diseases and rising healthcare expenditure are the substantial driving factors of the market across the globe. In addition, growing acceptance due to their cost-effectiveness is also boosting the market growth over the upcoming years. Furthermore, patent expiry of biologic products is the major factor which creating numerous opportunity in the market over the coming years. However, complications associated with manufacturing of G-CSF biosimilars are the factors which limiting the market growth of G-CSF Biosimilars over the coming years. The regional analysis of Global G-CSF Biosimilars Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.
The major market player included in this report are:
• Pfizer
• Novartis
• Roche
• Merck & Co.
• Sanofi
• Johnson & Johnson
• Gilead Science
• GlaxoSmithKline
• AbbVie
• Amgen
• AstraZeneca
• Bayer
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
 Human Growth Hormone
 Erythropoietin
 Monoclonal Antibodies
 Insulin
 Interferon
 Granulocyte-Colony Stimulating Factor
By Application:
 Blood Disorders
 Oncology Diseases
 Chronic and Autoimmune Diseases
 Growth Hormone Deficiencies
By Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
 Asia Pacific
o China
o India
o Japan
 Latin America
o Brazil
o Mexico
 Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025
Target Audience of the Global G-CSF Biosimilars Market in Market Study:
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Related Reports
Proof of Quality & Reliability
